BACKGROUND: One of the long term complications of diabetes is the non-enzymatic addition of glucose to proteins in blood, such as human serum albumin (HSA), which leads to the formation of an Amadori product and advanced glycation end products (AGEs). This study uses (16)O/(18)O-labeling and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to provide quantitative data on the extent of modification that occurs in the presence of glucose at various regions in the structure of minimally glycated HSA. METHODS: Normal HSA, with no significant levels of glycation, was digested by various proteolytic enzymes in the presence of water, while a similar sample containing in vitro glycated HSA was digested in (18)O-enriched water. These samples were then mixed and the (16)O/(18)O ratios were measured for peptides in each digest. The values obtained for the (16)O/(18)O ratios of the detected peptides for the mixed sample were used to determine the degree of modification that occurred in various regions of glycated HSA. RESULTS: Peptides containing arginines 114, 81, or 218 and lysines 413, 432, 159, 212, or 323 were found to have (16)O/(18)O ratios greater than a cut off value of 2.0 (i.e., a cut off value based on results noted when using only normal HSA as a reference). A qualitative comparison of the (16)O- and (18)O-labeled digests indicated that lysines 525 and 439 also had significant degrees of modification. The modifications that occurred at these sites were variations of fructosyl-lysine and AGEs which included 1-alkyl-2-formyl-3,4-glycoyl-pyrole and pyrraline. CONCLUSIONS: Peptides containing arginine 218 and lysines 212, 413, 432, and 439 contained high levels of modification and are also present near the major drug binding sites on HSA. This result is clinically relevant because it suggests the glycation of HSA may alter its ability to bind various drugs and small solutes in blood. Copyright 2010 Elsevier B.V. All rights reserved.
BACKGROUND: One of the long term complications of diabetes is the non-enzymatic addition of glucose to proteins in blood, such as humanserum albumin (HSA), which leads to the formation of an Amadori product and advanced glycation end products (AGEs). This study uses (16)O/(18)O-labeling and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to provide quantitative data on the extent of modification that occurs in the presence of glucose at various regions in the structure of minimally glycated HSA. METHODS: Normal HSA, with no significant levels of glycation, was digested by various proteolytic enzymes in the presence of water, while a similar sample containing in vitro glycated HSA was digested in (18)O-enriched water. These samples were then mixed and the (16)O/(18)O ratios were measured for peptides in each digest. The values obtained for the (16)O/(18)O ratios of the detected peptides for the mixed sample were used to determine the degree of modification that occurred in various regions of glycated HSA. RESULTS:Peptides containing arginines 114, 81, or 218 and lysines 413, 432, 159, 212, or 323 were found to have (16)O/(18)O ratios greater than a cut off value of 2.0 (i.e., a cut off value based on results noted when using only normal HSA as a reference). A qualitative comparison of the (16)O- and (18)O-labeled digests indicated that lysines 525 and 439 also had significant degrees of modification. The modifications that occurred at these sites were variations of fructosyl-lysine and AGEs which included 1-alkyl-2-formyl-3,4-glycoyl-pyrole and pyrraline. CONCLUSIONS:Peptides containing arginine 218 and lysines 212, 413, 432, and 439 contained high levels of modification and are also present near the major drug binding sites on HSA. This result is clinically relevant because it suggests the glycation of HSA may alter its ability to bind various drugs and small solutes in blood. Copyright 2010 Elsevier B.V. All rights reserved.
Authors: O A Mirgorodskaya; Y P Kozmin; M I Titov; R Körner; C P Sönksen; P Roepstorff Journal: Rapid Commun Mass Spectrom Date: 2000 Impact factor: 2.419
Authors: X Zhang; K F Medzihradszky; J Cunningham; P D Lee; C L Rognerud; C N Ou; P Harmatz; H E Witkowska Journal: J Chromatogr B Biomed Sci Appl Date: 2001-08-05
Authors: Leigh Willard; Anuj Ranjan; Haiyan Zhang; Hassan Monzavi; Robert F Boyko; Brian D Sykes; David S Wishart Journal: Nucleic Acids Res Date: 2003-07-01 Impact factor: 16.971
Authors: Naila Ahmed; Ognian K Argirov; Harjit S Minhas; Carlos A A Cordeiro; Paul J Thornalley Journal: Biochem J Date: 2002-05-15 Impact factor: 3.857
Authors: Keshore R Bidasee; Karuna Nallani; Yongqi Yu; Ross R Cocklin; Yinong Zhang; Mu Wang; U Deniz Dincer; Henry R Besch Journal: Diabetes Date: 2003-07 Impact factor: 9.461
Authors: Qian Dong; Xinjian Yan; Lisa E Kilpatrick; Yuxue Liang; Yuri A Mirokhin; Jeri S Roth; Paul A Rudnick; Stephen E Stein Journal: Mol Cell Proteomics Date: 2014-06-02 Impact factor: 5.911
Authors: Jeanethe Anguizola; Ryan Matsuda; Omar S Barnaby; K S Hoy; Chunling Wa; Erin DeBolt; Michelle Koke; David S Hage Journal: Clin Chim Acta Date: 2013-07-24 Impact factor: 3.786